{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T18:13:01Z","timestamp":1778263981164,"version":"3.51.4"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,28]]},"DOI":"10.7759\/cureus.46152","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T22:01:53Z","timestamp":1695938513000},"source":"Crossref","is-referenced-by-count":10,"title":["Heart Failure With Preserved Ejection Fraction: An Evolving Understanding"],"prefix":"10.7759","author":[{"given":"Sunanda","family":"Tah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maham","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ali","family":"Lak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol","family":"Gostomczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elhama","family":"Jami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahendra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouhammad","family":"Sharifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Arain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan TE","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006, 355:251-9. 10.1056\/NEJMoa052256","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2016.12.031","article-title":"Heart failure with preserved ejection fraction: diagnosis and management","volume":"130","author":"Oren O","year":"2017","unstructured":"Oren O, Goldberg S. Heart failure with preserved ejection fraction: diagnosis and management. Am J Med. 2017, 130:510-6. 10.1016\/j.amjmed.2016.12.031","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug BA","year":"2020","unstructured":"Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020, 17:559-73. 10.1038\/s41569-020-0363-2","journal-title":"Nat Rev Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske B","year":"2019","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, et al.. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019, 40:3297-317. 10.1093\/eurheartj\/ehz641","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology","volume":"28","author":"Paulus WJ","year":"2007","unstructured":"Paulus WJ, Tsch\u00f6pe C, Sanderson JE, et al.. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007, 28:2539-50. 10.1093\/eurheartj\/ehm037","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.07.046","article-title":"Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis","volume":"43","author":"Hogg K","year":"2004","unstructured":"Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004, 43:317-27. 10.1016\/j.jacc.2003.07.046","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2005.02.010","article-title":"Epidemiology of diastolic heart failure","volume":"47","author":"Owan TE","year":"2005","unstructured":"Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005, 47:320-32. 10.1016\/j.pcad.2005.02.010","journal-title":"Prog Cardiovasc Dis"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/0735-1097(95)00381-9","article-title":"Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective","volume":"26","author":"Vasan RS","year":"1995","unstructured":"Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995, 26:1565-74.","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009884820941","article-title":"Incidence and epidemiology of heart failure","volume":"5","author":"Kannel WB","year":"2000","unstructured":"Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000, 5:167-73. 10.1023\/A:1009884820941","journal-title":"Heart Fail Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1998.1280","article-title":"Incidence and aetiology of heart failure; a population-based study","volume":"20","author":"Cowie MR","year":"1999","unstructured":"Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, Sutton GC. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999, 20:421-8. 10.1053\/euhj.1998.1280","journal-title":"Eur Heart J"},{"key":"ref11","article-title":"Framingham risk score inadequately predicts cardiac risk in young patients presenting with a first myocardial infarction","volume":"39","author":"Lee GK","year":"2010","unstructured":"Lee GK, Lee LC, Liu CW, et al.. Framingham risk score inadequately predicts cardiac risk in young patients presenting with a first myocardial infarction. Ann Acad Med Singap. 2010, 39:163-7.","journal-title":"Ann Acad Med Singap"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs052","article-title":"Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy","volume":"14","author":"Mureddu GF","year":"2012","unstructured":"Mureddu GF, Agabiti N, Rizzello V, et al.. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail. 2012, 14:718-29. 10.1093\/eurjhf\/hfs052","journal-title":"Eur J Heart Fail"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(01)01700-4","article-title":"Confirmation of a heart failure epidemic: findings from the resource utilization among congestive heart failure (reach) study","volume":"39","author":"McCullough PA","year":"2002","unstructured":"McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the resource utilization among congestive heart failure (reach) study. J Am Coll Cardiol. 2002, 39:60-9.","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1016\/S0025-6196(12)60063-9","article-title":"The incidence and prevalence of congestive heart failure in Rochester, Minnesota","volume":"68","author":"Rodeheffer RJ","year":"1993","unstructured":"Rodeheffer RJ, Jacobsen SJ, Kottke TE, McCann HA, Bailey KR, Ballard DJ. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc. 1993, 68:1143-50.","journal-title":"Mayo Clin Proc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"348","author":"Jessup M","year":"2003","unstructured":"Jessup M, Brozena S. Heart failure. N Engl J Med. 2003, 348:2007-18. 10.1056\/NEJMra021498","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.04.065","article-title":"Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy","volume":"52","author":"Sharp A","year":"2008","unstructured":"Sharp A, Tapp R, Francis DP, et al.. Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. J Am Coll Cardiol. 2008, 52:1015-21. 10.1016\/j.jacc.2008.04.065","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052948","article-title":"Association of parental heart failure with risk of heart failure in offspring","volume":"355","author":"Lee DS","year":"2006","unstructured":"Lee DS, Pencina MJ, Benjamin EJ, et al.. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006, 355:138-47. 10.1056\/NEJMoa052948","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction","volume":"10","author":"Oktay AA","year":"2013","unstructured":"Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013, 10:401-10. 10.1007\/s11897-013-0155-7","journal-title":"Curr Heart Fail Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.430","article-title":"Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use","volume":"17","author":"D'Elia E","year":"2015","unstructured":"D'Elia E, Vaduganathan M, Gori M, Gavazzi A, Butler J, Senni M. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail. 2015, 17:1231-9. 10.1002\/ejhf.430","journal-title":"Eur J Heart Fail"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle","volume":"350","author":"Zile MR","year":"2004","unstructured":"Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004, 350:1953-9. 10.1056\/NEJMoa032566","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug BA","year":"2014","unstructured":"Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014, 11:507-15. 10.1038\/nrcardio.2014.83","journal-title":"Nat Rev Cardiol"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1016\/0735-1097(93)90850-Z","article-title":"Diastolic failure: pathophysiology and therapeutic implications","volume":"22","author":"Brutsaert DL","year":"1993","unstructured":"Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol. 1993, 22:318-25.","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.55.091902.104417","article-title":"Left ventricular diastolic dysfunction and diastolic heart failure","volume":"55","author":"Gaasch WH","year":"2004","unstructured":"Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004, 55:373-94. 10.1146\/annurev.med.55.091902.104417","journal-title":"Annu Rev Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw241","article-title":"Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction","volume":"37","author":"Borlaug BA","year":"2016","unstructured":"Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J. 2016, 37:3293-302. 10.1093\/eurheartj\/ehw241","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198501313120504","article-title":"Hypertensive hypertrophic cardiomyopathy of the elderly","volume":"312","author":"Topol EJ","year":"1985","unstructured":"Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985, 312:277-83. 10.1056\/NEJM198501313120504","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/hc3201.094226","article-title":"Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?","volume":"104","author":"Zile MR","year":"2001","unstructured":"Zile MR, Gaasch WH, Carroll JD, et al.. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?. Circulation. 2001, 104:779-82. 10.1161\/hc3201.094226","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.659763","article-title":"Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota","volume":"115","author":"Lam CS","year":"2007","unstructured":"Lam CS, Roger VL, Rodeheffer RJ, et al.. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007, 115:1982-90. 10.1161\/CIRCULATIONAHA.106.659763","journal-title":"Circulation"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.05.013","article-title":"Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction","volume":"54","author":"Borlaug BA","year":"2009","unstructured":"Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009, 54:410-8. 10.1016\/j.jacc.2009.05.013","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile MR","year":"2011","unstructured":"Zile MR, Gottdiener JS, Hetzel SJ, et al.. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011, 124:2491-501. 10.1161\/CIRCULATIONAHA.110.011031","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.587519","article-title":"Myocardial structure and function differ in systolic and diastolic heart failure","volume":"113","author":"van Heerebeek L","year":"2006","unstructured":"van Heerebeek L, Borb\u00e9ly A, Niessen HW, et al.. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006, 113:1966-73. 10.1161\/CIRCULATIONAHA.105.587519","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000155257.33485.6D","article-title":"Cardiomyocyte stiffness in diastolic heart failure","volume":"111","author":"Borb\u00e9ly A","year":"2005","unstructured":"Borb\u00e9ly A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005, 111:774-81. 10.1161\/01.CIR.0000155257.33485.6D","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug BA","year":"2011","unstructured":"Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011, 32:670-9. 10.1093\/eurheartj\/ehq426","journal-title":"Eur Heart J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2006.05.003","article-title":"Mechanisms of diastolic dysfunction in heart failure","volume":"16","author":"Borlaug BA","year":"2006","unstructured":"Borlaug BA, Kass DA. Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med. 2006, 16:273-9. 10.1016\/j.tcm.2006.05.003","journal-title":"Trends Cardiovasc Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin","volume":"131","author":"Zile MR","year":"2015","unstructured":"Zile MR, Baicu CF, Ikonomidis JS, et al.. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015, 131:1247-59. 10.1161\/CIRCULATIONAHA.114.013215","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart\u00a0failure with preserved ejection\u00a0fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn VS","year":"2020","unstructured":"Hahn VS, Yanek LR, Vaishnav J, et al.. Endomyocardial biopsy characterization of heart\u00a0failure with preserved ejection\u00a0fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020, 8:712-24. 10.1016\/j.jchf.2020.04.007","journal-title":"JACC Heart Fail"},{"key":"ref36","article-title":"Impact of comorbidities on myocardial remodeling and dysfunction in heart failure with preserved ejection fraction","volume":"1","author":"van Heerebeek L","year":"2014","unstructured":"van Heerebeek L, Paulus WJ. Impact of comorbidities on myocardial remodeling and dysfunction in heart failure with preserved ejection fraction. SOJ Pharm Pharm Sci. 2014, 1:1-20.","journal-title":"SOJ Pharm Pharm Sci"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.301286","article-title":"Gigantic business: titin properties and function through thick and thin","volume":"114","author":"Linke WA","year":"2014","unstructured":"Linke WA, Hamdani N. Gigantic business: titin properties and function through thick and thin. Circ Res. 2014, 114:1052-68. 10.1161\/CIRCRESAHA.114.301286","journal-title":"Circ Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.198465","article-title":"PKC phosphorylation of titin's PEVK element: a novel and conserved pathway for modulating myocardial stiffness","volume":"105","author":"Hidalgo C","year":"2009","unstructured":"Hidalgo C, Hudson B, Bogomolovas J, et al.. PKC phosphorylation of titin's PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ Res. 2009, 105:631-8, 17 p following 638. 10.1161\/CIRCRESAHA.109.198465","journal-title":"Circ Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.193326","article-title":"Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium","volume":"104","author":"Borb\u00e9ly A","year":"2009","unstructured":"Borb\u00e9ly A, Falcao-Pires I, van Heerebeek L, et al.. Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res. 2009, 104:780-6. 10.1161\/CIRCRESAHA.108.193326","journal-title":"Circ Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.200409177","article-title":"Phosphorylation of titin modulates passive stiffness of cardiac muscle in a titin isoform-dependent manner","volume":"125","author":"Fukuda N","year":"2005","unstructured":"Fukuda N, Wu Y, Nair P, Granzier HL. Phosphorylation of titin modulates passive stiffness of cardiac muscle in a titin isoform-dependent manner. J Gen Physiol. 2005, 125:257-71. 10.1085\/jgp.200409177","journal-title":"J Gen Physiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00407.2010","article-title":"Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse","volume":"301","author":"Reed AL","year":"2011","unstructured":"Reed AL, Tanaka A, Sorescu D, et al.. Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. Am J Physiol Heart Circ Physiol. 2011, 301:H824-31. 10.1152\/ajpheart.00407.2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvs275","article-title":"Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice","volume":"96","author":"Chiao YA","year":"2012","unstructured":"Chiao YA, Ramirez TA, Zamilpa R, et al.. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res. 2012, 96:444-55. 10.1093\/cvr\/cvs275","journal-title":"Cardiovasc Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.638569","article-title":"Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction","volume":"115","author":"Martos R","year":"2007","unstructured":"Martos R, Baugh J, Ledwidge M, et al.. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007, 115:888-95. 10.1161\/CIRCULATIONAHA.106.638569","journal-title":"Circulation"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2014.43739","article-title":"Heart diastolic dysfunction in patients with systemic sclerosis","volume":"10","author":"Ciurzy\u0144ski M","year":"2014","unstructured":"Ciurzy\u0144ski M, Bienias P, Irzyk K, et al.. Heart diastolic dysfunction in patients with systemic sclerosis. Arch Med Sci. 2014, 10:445-54. 10.5114\/aoms.2014.43739","journal-title":"Arch Med Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2012.03.009","article-title":"Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice","volume":"52","author":"Fraysse B","year":"2012","unstructured":"Fraysse B, Weinberger F, Bardswell SC, et al.. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol. 2012, 52:1299-307. 10.1016\/j.yjmcc.2012.03.009","journal-title":"J Mol Cell Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2012.12.003","article-title":"Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties","volume":"56","author":"Jeong EM","year":"2013","unstructured":"Jeong EM, Monasky MM, Gu L, et al.. Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. J Mol Cell Cardiol. 2013, 56:44-54. 10.1016\/j.yjmcc.2012.12.003","journal-title":"J Mol Cell Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1671","article-title":"Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"22","author":"Yang JH","year":"2020","unstructured":"Yang JH, Obokata M, Reddy YN, Redfield MM, Lerman A, Borlaug BA. Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2020, 22:432-41. 10.1002\/ejhf.1671","journal-title":"Eur J Heart Fail"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(01)01447-4","article-title":"Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance","volume":"38","author":"Hundley WG","year":"2001","unstructured":"Hundley WG, Kitzman DW, Morgan TM, et al.. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol. 2001, 38:796-802.","journal-title":"J Am Coll Cardiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001192","article-title":"Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study","volume":"7","author":"Mohammed SF","year":"2014","unstructured":"Mohammed SF, Borlaug BA, McNulty S, et al.. Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail. 2014, 7:580-9. 10.1161\/CIRCHEARTFAILURE.114.001192","journal-title":"Circ Heart Fail"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1159\/000501100","article-title":"Endothelin 1 is associated with heart failure hospitalization and long-term mortality in patients with heart failure with preserved ejection fraction and pulmonary hypertension","volume":"143","author":"Chowdhury MA","year":"2019","unstructured":"Chowdhury MA, Moukarbel GV, Gupta R, Frank SM, Anderson AM, Liu LC, Khouri SJ. Endothelin 1 is associated with heart failure hospitalization and long-term mortality in patients with heart failure with preserved ejection fraction and pulmonary hypertension. Cardiology. 2019, 143:124-33. 10.1159\/000501100","journal-title":"Cardiology"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella GG","year":"2019","unstructured":"Schiattarella GG, Altamirano F, Tong D, et al.. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019, 568:351-6. 10.1038\/s41586-019-1100-z","journal-title":"Nature"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed SF","year":"2015","unstructured":"Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015, 131:550-9. 10.1161\/CIRCULATIONAHA.114.009625","journal-title":"Circulation"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001293","article-title":"Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction","volume":"3","author":"van Empel VP","year":"2014","unstructured":"van Empel VP, Mariani J, Borlaug BA, Kaye DM. Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc. 2014, 3:e001293. 10.1161\/JAHA.114.001293","journal-title":"J Am Heart Assoc"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-020-0778-2","article-title":"Perturbations in myocardial perfusion and oxygen balance in swine with multiple risk factors: a novel model of ischemia and no obstructive coronary artery disease","volume":"115","author":"van de Wouw J","year":"2020","unstructured":"van de Wouw J, Sorop O, van Drie RW, et al.. Perturbations in myocardial perfusion and oxygen balance in swine with multiple risk factors: a novel model of ischemia and no obstructive coronary artery disease. Basic Res Cardiol. 2020, 115:21. 10.1007\/s00395-020-0778-2","journal-title":"Basic Res Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-014-1480-8","article-title":"Heart failure with preserved ejection fraction","volume":"466","author":"Gladden JD","year":"2014","unstructured":"Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Arch. 2014, 466:1037-53. 10.1007\/s00424-014-1480-8","journal-title":"Pflugers Arch"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2015.09.003","article-title":"Vascular and microvascular endothelial function in heart failure with preserved ejection fraction","volume":"22","author":"Mar\u00e9chaux S","year":"2016","unstructured":"Mar\u00e9chaux S, Samson R, van Belle E, et al.. Vascular and microvascular endothelial function in heart failure with preserved ejection fraction. J Card Fail. 2016, 22:3-11. 10.1016\/j.cardfail.2015.09.003","journal-title":"J Card Fail"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000292","article-title":"Heart failure with preserved ejection fraction in hypertension","volume":"31","author":"Teo LY","year":"2016","unstructured":"Teo LY, Chan LL, Lam CS. Heart failure with preserved ejection fraction in hypertension. Curr Opin Cardiol. 2016, 31:410-6. 10.1097\/HCO.0000000000000292","journal-title":"Curr Opin Cardiol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308403","article-title":"Evidence of microvascular dysfunction in heart failure with preserved ejection fraction","volume":"102","author":"Lee JF","year":"2016","unstructured":"Lee JF, Barrett-O'Keefe Z, Garten RS, et al.. Evidence of microvascular dysfunction in heart failure with preserved ejection fraction. Heart. 2016, 102:278-84. 10.1136\/heartjnl-2015-308403","journal-title":"Heart"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gls099","article-title":"Relationship of flow-mediated arterial dilation and exercise capacity in older patients with heart failure and preserved ejection fraction","volume":"68","author":"Haykowsky MJ","year":"2013","unstructured":"Haykowsky MJ, Herrington DM, Brubaker PH, Morgan TM, Hundley WG, Kitzman DW. Relationship of flow-mediated arterial dilation and exercise capacity in older patients with heart failure and preserved ejection fraction. J Gerontol A Biol Sci Med Sci. 2013, 68:161-7. 10.1093\/gerona\/gls099","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-014-0421-1","article-title":"Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition","volume":"109","author":"Fraccarollo D","year":"2014","unstructured":"Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Sch\u00e4fer A, Bauersachs J. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. Basic Res Cardiol. 2014, 109:421. 10.1007\/s00395-014-0421-1","journal-title":"Basic Res Cardiol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.717702","article-title":"Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction","volume":"118","author":"Fraccarollo D","year":"2008","unstructured":"Fraccarollo D, Widder JD, Galuppo P, et al.. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation. 2008, 118:818-27. 10.1161\/CIRCULATIONAHA.107.717702","journal-title":"Circulation"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfp005","article-title":"Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer","volume":"11","author":"Sch\u00e4fer A","year":"2009","unstructured":"Sch\u00e4fer A, Fraccarollo D, Widder J, Eigenthaler M, Ertl G, Bauersachs J. Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer. Eur J Heart Fail. 2009, 11:336-41. 10.1093\/eurjhf\/hfp005","journal-title":"Eur J Heart Fail"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003806","article-title":"Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model","volume":"10","author":"Gevaert AB","year":"2017","unstructured":"Gevaert AB, Shakeri H, Leloup AJ, et al.. Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model. Circ Heart Fail. 2017, 10:1161. 10.1161\/CIRCHEARTFAILURE.116.003806","journal-title":"Circ Heart Fail"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000257912.78915.af","article-title":"Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1","volume":"100","author":"Thum T","year":"2007","unstructured":"Thum T, Hoeber S, Froese S, et al.. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res. 2007, 100:434-43. 10.1161\/01.RES.0000257912.78915.af","journal-title":"Circ Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106830","article-title":"Myeloperoxidase, a leukocyte-derived vascular NO oxidase","volume":"296","author":"Eiserich JP","year":"2002","unstructured":"Eiserich JP, Baldus S, Brennan ML, et al.. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002, 296:2391-4. 10.1126\/science.1106830","journal-title":"Science"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021426","article-title":"Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction","volume":"197","author":"Askari AT","year":"2003","unstructured":"Askari AT, Brennan ML, Zhou X, et al.. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003, 197:615-24. 10.1084\/jem.20021426","journal-title":"J Exp Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2124","article-title":"Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation","volume":"16","author":"Rudolph V","year":"2010","unstructured":"Rudolph V, Andri\u00e9 RP, Rudolph TK, et al.. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010, 16:470-4. 10.1038\/nm.2124","journal-title":"Nat Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy038","article-title":"Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening","volume":"114","author":"Sorop O","year":"2018","unstructured":"Sorop O, Heinonen I, van Kranenburg M, et al.. Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. Cardiovasc Res. 2018, 114:954-64. 10.1093\/cvr\/cvy038","journal-title":"Cardiovasc Res"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-018-0711-0","article-title":"Of mice and men: models and mechanisms of diabetic cardiomyopathy","volume":"114","author":"Riehle C","year":"2018","unstructured":"Riehle C, Bauersachs J. Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Res Cardiol. 2018, 114:2. 10.1007\/s00395-018-0711-0","journal-title":"Basic Res Cardiol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.306206","article-title":"Insulin signaling and heart failure","volume":"118","author":"Riehle C","year":"2016","unstructured":"Riehle C, Abel ED. Insulin signaling and heart failure. Circ Res. 2016, 118:1151-69. 10.1161\/CIRCRESAHA.116.306206","journal-title":"Circ Res"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.942","article-title":"Immune mechanisms in heart failure","volume":"19","author":"Zhang Y","year":"2017","unstructured":"Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Eur J Heart Fail. 2017, 19:1379-89. 10.1002\/ejhf.942","journal-title":"Eur J Heart Fail"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0064-0","article-title":"Myeloid cell contributions to cardiovascular health and disease","volume":"24","author":"Nahrendorf M","year":"2018","unstructured":"Nahrendorf M. Myeloid cell contributions to cardiovascular health and disease. Nat Med. 2018, 24:711-20. 10.1038\/s41591-018-0064-0","journal-title":"Nat Med"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2015.11.015","article-title":"Monocyte and macrophage contributions to cardiac remodeling","volume":"93","author":"Hulsmans M","year":"2016","unstructured":"Hulsmans M, Sam F, Nahrendorf M. Monocyte and macrophage contributions to cardiac remodeling. J Mol Cell Cardiol. 2016, 93:149-55. 10.1016\/j.yjmcc.2015.11.015","journal-title":"J Mol Cell Cardiol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw002","article-title":"Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype","volume":"38","author":"Horckmans M","year":"2017","unstructured":"Horckmans M, Ring L, Duchene J, et al.. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur Heart J. 2017, 38:187-97. 10.1093\/eurheartj\/ehw002","journal-title":"Eur Heart J"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070885","article-title":"The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions","volume":"204","author":"Nahrendorf M","year":"2007","unstructured":"Nahrendorf M, Swirski FK, Aikawa E, et al.. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007, 204:3037-47. 10.1084\/jem.20070885","journal-title":"J Exp Med"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a015268","article-title":"Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure","volume":"18","author":"Devaux B","year":"1997","unstructured":"Devaux B, Scholz D, Hirche A, Kl\u00f6vekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 1997, 18:470-9. 10.1093\/oxfordjournals.eurheartj.a015268","journal-title":"Eur Heart J"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.301720","article-title":"Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis","volume":"114","author":"Ismahil MA","year":"2014","unstructured":"Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res. 2014, 114:266-82. 10.1161\/CIRCRESAHA.113.301720","journal-title":"Circ Res"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.041818","article-title":"Deliberating the diagnostic dilemma of heart failure with preserved ejection fraction","volume":"142","author":"Ho JE","year":"2020","unstructured":"Ho JE, Redfield MM, Lewis GD, Paulus WJ, Lam CS. Deliberating the diagnostic dilemma of heart failure with preserved ejection fraction. Circulation. 2020, 142:1770-80. 10.1161\/CIRCULATIONAHA.119.041818","journal-title":"Circulation"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz713","article-title":"The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction","volume":"40","author":"Reddy YN","year":"2019","unstructured":"Reddy YN, Obokata M, Wiley B, et al.. The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. Eur Heart J. 2019, 40:3721-30. 10.1093\/eurheartj\/ehz713","journal-title":"Eur Heart J"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial","volume":"7","author":"Shah AM","year":"2014","unstructured":"Shah AM, Claggett B, Sweitzer NK, et al.. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014, 7:740-51. 10.1161\/CIRCHEARTFAILURE.114.001583","journal-title":"Circ Heart Fail"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic features of patients\u00a0with heart\u00a0failure and preserved\u00a0left ventricular ejection fraction","volume":"74","author":"Shah AM","year":"2019","unstructured":"Shah AM, Cikes M, Prasad N, et al.. Echocardiographic features of patients\u00a0with heart\u00a0failure and preserved\u00a0left ventricular ejection fraction. J Am Coll Cardiol. 2019, 74:2858-73. 10.1016\/j.jacc.2019.09.063","journal-title":"J Am Coll Cardiol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.05.014","article-title":"Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction","volume":"110","author":"Anjan VY","year":"2012","unstructured":"Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M, Shah SJ. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012, 110:870-6. 10.1016\/j.amjcard.2012.05.014","journal-title":"Am J Cardiol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy CW","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013, 128:e240-327. 10.1161\/CIR.0b013e31829e8776","journal-title":"Circulation"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004750","article-title":"Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure","volume":"11","author":"Eisman AS","year":"2018","unstructured":"Eisman AS, Shah RV, Dhakal BP, et al.. Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure. Circ Heart Fail. 2018, 11:e004750. 10.1161\/CIRCHEARTFAILURE.117.004750","journal-title":"Circ Heart Fail"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701","article-title":"Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction","volume":"3","author":"Borlaug BA","year":"2010","unstructured":"Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010, 3:588-95. 10.1161\/CIRCHEARTFAILURE.109.930701","journal-title":"Circ Heart Fail"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy331","article-title":"Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease","volume":"39","author":"Gorter TM","year":"2018","unstructured":"Gorter TM, Obokata M, Reddy YN, Melenovsky V, Borlaug BA. Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. Eur Heart J. 2018, 39:2825-35. 10.1093\/eurheartj\/ehy331","journal-title":"Eur Heart J"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1776","article-title":"Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure","volume":"22","author":"Dewan P","year":"2020","unstructured":"Dewan P, Jackson A, Lam CS, et al.. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. Eur J Heart Fail. 2020, 22:898-901. 10.1002\/ejhf.1776","journal-title":"Eur J Heart Fail"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland JG","year":"2018","unstructured":"Cleland JG, Bunting KV, Flather MD, et al.. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018, 39:26-35. 10.1093\/eurheartj\/ehx564","journal-title":"Eur Heart J"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy YN","year":"2018","unstructured":"Reddy YN, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018, 138:861-70. 10.1161\/CIRCULATIONAHA.118.034646","journal-title":"Circulation"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050757","article-title":"Evaluation of 2 existing diagnostic scores for heart failure with preserved ejection fraction against a comprehensively phenotyped cohort","volume":"143","author":"Churchill TW","year":"2021","unstructured":"Churchill TW, Li SX, Curreri L, et al.. Evaluation of 2 existing diagnostic scores for heart failure with preserved ejection fraction against a comprehensively phenotyped cohort. Circulation. 2021, 143:289-91. 10.1161\/CIRCULATIONAHA.120.050757","journal-title":"Circulation"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-20-244","article-title":"Should CMR be the default imaging modality in clinical trials for heart failure?","volume":"10","author":"Hundertmark M","year":"2020","unstructured":"Hundertmark M. Should CMR be the default imaging modality in clinical trials for heart failure?. Cardiovasc Diagn Ther. 2020, 10:554-8. 10.21037\/cdt-20-244","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-011-9985-0","article-title":"Sources of variation and bias in assessing left ventricular volumes and dyssynchrony using three-dimensional echocardiography","volume":"28","author":"Muraru D","year":"2012","unstructured":"Muraru D, Badano LP, Ermacora D, Piccoli G, Iliceto S. Sources of variation and bias in assessing left ventricular volumes and dyssynchrony using three-dimensional echocardiography. Int J Cardiovasc Imaging. 2012, 28:1357-68. 10.1007\/s10554-011-9985-0","journal-title":"Int J Cardiovasc Imaging"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.08.058","article-title":"A meta-analysis and investigation for the source of bias of left ventricular volumes and function by three-dimensional echocardiography in comparison with magnetic resonance imaging","volume":"107","author":"Shimada YJ","year":"2011","unstructured":"Shimada YJ, Shiota T. A meta-analysis and investigation for the source of bias of left ventricular volumes and function by three-dimensional echocardiography in comparison with magnetic resonance imaging. Am J Cardiol. 2011, 107:126-38. 10.1016\/j.amjcard.2010.08.058","journal-title":"Am J Cardiol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering4020030","article-title":"4D Flow Assessment of Vorticity in Right Ventricular Diastolic Dysfunction","volume":"4","author":"Browning JR","year":"2017","unstructured":"Browning JR, Hertzberg JR, Schroeder JD, Fenster BE. 4D Flow Assessment of Vorticity in Right Ventricular Diastolic Dysfunction. Bioengineering (Basel). 2017, 4:10.3390\/bioengineering4020030","journal-title":"Bioengineering (Basel)"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-018-0483-6","article-title":"Left ventricular blood flow kinetic energy after myocardial infarction - insights from 4D flow cardiovascular magnetic resonance","volume":"20","author":"Garg P","year":"2018","unstructured":"Garg P, Crandon S, Swoboda PP, et al.. Left ventricular blood flow kinetic energy after myocardial infarction - insights from 4D flow cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2018, 20:61. 10.1186\/s12968-018-0483-6","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2019.02.031","article-title":"CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF: current role and future perspectives","volume":"13","author":"Chamsi-Pasha MA","year":"2020","unstructured":"Chamsi-Pasha MA, Zhan Y, Debs D, Shah DJ. CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF: current role and future perspectives. JACC Cardiovasc Imaging. 2020, 13:283-96. 10.1016\/j.jcmg.2019.02.031","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.05.012","article-title":"Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency","volume":"54","author":"Phan TT","year":"2009","unstructured":"Phan TT, Abozguia K, Nallur Shivu G, et al.. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009, 54:402-9. 10.1016\/j.jacc.2009.05.012","journal-title":"J Am Coll Cardiol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.31.1157","article-title":"Effects of cardiac energy efficiency in diastolic heart failure: assessment with positron emission tomography with 11C-acetate","volume":"31","author":"Hasegawa S","year":"2008","unstructured":"Hasegawa S, Yamamoto K, Sakata Y, et al.. Effects of cardiac energy efficiency in diastolic heart failure: assessment with positron emission tomography with 11C-acetate. Hypertens Res. 2008, 31:1157-62. 10.1291\/hypres.31.1157","journal-title":"Hypertens Res"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.76.3.687","article-title":"Delineation of myocardial oxygen utilization with carbon-11-labeled acetate","volume":"76","author":"Brown M","year":"1987","unstructured":"Brown M, Marshall DR, Sobel BE, Bergmann SR. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation. 1987, 76:687-96. 10.1161\/01.cir.76.3.687","journal-title":"Circulation"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi406","article-title":"The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements","volume":"26","author":"Tsch\u00f6pe C","year":"2005","unstructured":"Tsch\u00f6pe C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005, 26:2277-84. 10.1093\/eurheartj\/ehi406","journal-title":"Eur Heart J"},{"key":"ref102","article-title":"Association of diastolic dysfunction with N-terminal Pro-B-type natriuretic peptide level in heart failure patients with preserved ejection fraction","volume":"28","author":"Islam MN","year":"2019","unstructured":"Islam MN, Chowdhury MS, Paul GK, Debnath RC, Shakil SS. Association of diastolic dysfunction with N-terminal Pro-B-type natriuretic peptide level in heart failure patients with preserved ejection fraction. Mymensingh Med J. 2019, 28:333-46.","journal-title":"Mymensingh Med J"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0b013e328320d82a","article-title":"Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure","volume":"24","author":"Parekh N","year":"2009","unstructured":"Parekh N, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr Opin Cardiol. 2009, 24:155-60. 10.1097\/HCO.0b013e328320d82a","journal-title":"Curr Opin Cardiol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction","volume":"61","author":"van Veldhuisen DJ","year":"2013","unstructured":"van Veldhuisen DJ, Linssen GC, Jaarsma T, et al.. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013, 61:1498-506. 10.1016\/j.jacc.2012.12.044","journal-title":"J Am Coll Cardiol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01764-x","article-title":"Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction-a systematic review and meta-analysis","volume":"18","author":"Remmelzwaal S","year":"2020","unstructured":"Remmelzwaal S, van Ballegooijen AJ, Schoonmade LJ, et al.. Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction-a systematic review and meta-analysis. BMC Med. 2020, 18:290. 10.1186\/s12916-020-01764-x","journal-title":"BMC Med"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller C","year":"2019","unstructured":"Mueller C, McDonald K, de Boer RA, et al.. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019, 21:715-31. 10.1002\/ejhf.1494","journal-title":"Eur J Heart Fail"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.08.007","article-title":"Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure","volume":"176","author":"Madamanchi C","year":"2014","unstructured":"Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014, 176:611-7. 10.1016\/j.ijcard.2014.08.007","journal-title":"Int J Cardiol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-011-9249-z","article-title":"The paradox of low BNP levels in obesity","volume":"17","author":"Clerico A","year":"2012","unstructured":"Clerico A, Giannoni A, Vittorini S, Emdin M. The paradox of low BNP levels in obesity. Heart Fail Rev. 2012, 17:81-96. 10.1007\/s10741-011-9249-z","journal-title":"Heart Fail Rev"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.21037\/jlpm.2019.01.03","article-title":"Pathophysiological mechanisms determining sex differences in circulating levels of cardiac natriuretic peptides and cardiac troponins","volume":"4","author":"Clerico A","year":"2019","unstructured":"Clerico A, Masotti S, Musetti V, Passino C. Pathophysiological mechanisms determining sex differences in circulating levels of cardiac natriuretic peptides and cardiac troponins. J Lab Precis Med. 2019, 4:21037. 10.21037\/jlpm.2019.01.03","journal-title":"J Lab Precis Med"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2012.12.014","article-title":"Biomarkers and diagnostics in heart failure","volume":"1832","author":"Gaggin HK","year":"2013","unstructured":"Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013, 1832:2442-50. 10.1016\/j.bbadis.2012.12.014","journal-title":"Biochim Biophys Acta"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2012.10.008","article-title":"Minor myocardial damage is a prevalent condition in patients with acute heart failure syndromes and preserved systolic function with long-term prognostic implications: a report from the CIAST-HF (Collaborative Italo-Argentinean Study on cardiac Troponin T in Heart Failure) study","volume":"18","author":"Perna ER","year":"2012","unstructured":"Perna ER, Aspromonte N, Cimbaro Canella JP, et al.. Minor myocardial damage is a prevalent condition in patients with acute heart failure syndromes and preserved systolic function with long-term prognostic implications: a report from the CIAST-HF (Collaborative Italo-Argentinean Study on cardiac Troponin T in Heart Failure) study. J Card Fail. 2012, 18:822-30. 10.1016\/j.cardfail.2012.10.008","journal-title":"J Card Fail"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.414","article-title":"Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction","volume":"17","author":"Sanders-van Wijk S","year":"2015","unstructured":"Sanders-van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, Brunner-La Rocca HP. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015, 17:1006-14. 10.1002\/ejhf.414","journal-title":"Eur J Heart Fail"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-016-0817-7","article-title":"Biomarkers in heart failure with preserved ejection fraction","volume":"24","author":"Meijers WC","year":"2016","unstructured":"Meijers WC, van der Velde AR, de Boer RA. Biomarkers in heart failure with preserved ejection fraction. Neth Heart J. 2016, 24:252-8. 10.1007\/s12471-016-0817-7","journal-title":"Neth Heart J"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus WJ","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013, 62:263-71. 10.1016\/j.jacc.2013.02.092","journal-title":"J Am Coll Cardiol"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2020.03.012","article-title":"Heart failure with preserved ejection fraction: a clustering approach to a heterogenous syndrome","volume":"113","author":"Schrub F","year":"2020","unstructured":"Schrub F, Oger E, Bidaut A, et al.. Heart failure with preserved ejection fraction: a clustering approach to a heterogenous syndrome. Arch Cardiovasc Dis. 2020, 113:381-90. 10.1016\/j.acvd.2020.03.012","journal-title":"Arch Cardiovasc Dis"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2021.02.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction","volume":"17","author":"Sorimachi H","year":"2021","unstructured":"Sorimachi H, Omote K, Borlaug BA. Clinical phenogroups in heart failure with preserved ejection fraction. Heart Fail Clin. 2021, 17:483-98. 10.1016\/j.hfc.2021.02.009","journal-title":"Heart Fail Clin"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(00)01165-6","article-title":"Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study","volume":"86","author":"Devereux RB","year":"2000","unstructured":"Devereux RB, Roman MJ, Liu JE, et al.. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol. 2000, 86:1090-6. 10.1016\/s0002-9149(00)01165-6","journal-title":"Am J Cardiol"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-8-200210150-00006","article-title":"Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study","volume":"137","author":"Gottdiener JS","year":"2002","unstructured":"Gottdiener JS, McClelland RL, Marshall R, et al.. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002, 137:631-9. 10.7326\/0003-4819-137-8-200210150-00006","journal-title":"Ann Intern Med"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia RS","year":"2006","unstructured":"Bhatia RS, Tu JV, Lee DS, et al.. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006, 355:260-9. 10.1056\/NEJMoa051530","journal-title":"N Engl J Med"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database","volume":"47","author":"Yancy CW","year":"2006","unstructured":"Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006, 47:76-84. 10.1016\/j.jacc.2005.09.022","journal-title":"J Am Coll Cardiol"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.18.2209","article-title":"Systolic and diastolic heart failure in the community","volume":"296","author":"Bursi F","year":"2006","unstructured":"Bursi F, Weston SA, Redfield MM, et al.. Systolic and diastolic heart failure in the community. JAMA. 2006, 296:2209-16. 10.1001\/jama.296.18.2209","journal-title":"JAMA"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.815944","article-title":"Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute","volume":"119","author":"Lee DS","year":"2009","unstructured":"Lee DS, Gona P, Vasan RS, et al.. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009, 119:3070-7. 10.1161\/CIRCULATIONAHA.108.815944","journal-title":"Circulation"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.10.022","article-title":"Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction","volume":"126","author":"Gurwitz JH","year":"2013","unstructured":"Gurwitz JH, Magid DJ, Smith DH, et al.. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. Am J Med. 2013, 126:393-400. 10.1016\/j.amjmed.2012.10.022","journal-title":"Am J Med"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND","volume":"34","author":"Brouwers FP","year":"2013","unstructured":"Brouwers FP, de Boer RA, van der Harst P, et al.. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013, 34:1424-31. 10.1093\/eurheartj\/eht066","journal-title":"Eur Heart J"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber Y","year":"2015","unstructured":"Gerber Y, Weston SA, Redfield MM, et al.. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015, 175:996-1004. 10.1001\/jamainternmed.2015.0924","journal-title":"JAMA Intern Med"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfq121","article-title":"Epidemiology and clinical course of heart failure with preserved ejection fraction","volume":"13","author":"Lam CS","year":"2011","unstructured":"Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011, 13:18-28. 10.1093\/eurjhf\/hfq121","journal-title":"Eur J Heart Fail"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-017-6754-x","article-title":"Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes","volume":"31","author":"Kristensen SL","year":"2017","unstructured":"Kristensen SL, Jhund PS, Lee MM, et al.. Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther. 2017, 31:545-9. 10.1007\/s10557-017-6754-x","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman DW","year":"2016","unstructured":"Kitzman DW, Brubaker P, Morgan T, et al.. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016, 315:36-46. 10.1001\/jama.2015.17346","journal-title":"JAMA"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.05.018","article-title":"The association of obesity and cardiometabolic traits with incident\u00a0HFpEF and HFrEF","volume":"6","author":"Savji N","year":"2018","unstructured":"Savji N, Meijers WC, Bartz TM, et al.. The association of obesity and cardiometabolic traits with incident\u00a0HFpEF and HFrEF. JACC Heart Fail. 2018, 6:701-9. 10.1016\/j.jchf.2018.05.018","journal-title":"JACC Heart Fail"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000221","article-title":"Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study","volume":"6","author":"Smith DH","year":"2013","unstructured":"Smith DH, Thorp ML, Gurwitz JH, et al.. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes. 2013, 6:333-42. 10.1161\/CIRCOUTCOMES.113.000221","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.161","article-title":"Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis","volume":"16","author":"Yeo TJ","year":"2014","unstructured":"Yeo TJ, Yeo PS, Ching-Chiew Wong R, et al.. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail. 2014, 16:1125-32. 10.1002\/ejhf.161","journal-title":"Eur J Heart Fail"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.01.046","article-title":"Anemia, mortality, and hospitalizations in heart failure with a preserved ejection fraction (from the TOPCAT Trial)","volume":"125","author":"Gupta K","year":"2020","unstructured":"Gupta K, Kalra R, Rajapreyar I, et al.. Anemia, mortality, and hospitalizations in heart failure with a preserved ejection fraction (from the TOPCAT Trial). Am J Cardiol. 2020, 125:1347-54. 10.1016\/j.amjcard.2020.01.046","journal-title":"Am J Cardiol"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n461","article-title":"Age dependent associations of risk factors with heart failure: pooled population based cohort study","volume":"372","author":"Tromp J","year":"2021","unstructured":"Tromp J, Paniagua SM, Lau ES, et al.. Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ. 2021, 372:n461. 10.1136\/bmj.n461","journal-title":"BMJ"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1227","article-title":"Heart failure with preserved ejection fraction in Asia","volume":"21","author":"Tromp J","year":"2019","unstructured":"Tromp J, Teng TH, Tay WT, et al.. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019, 21:23-36. 10.1002\/ejhf.1227","journal-title":"Eur J Heart Fail"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.05.052","article-title":"Age-related characteristics and outcomes of patients with heart\u00a0failure with preserved ejection fraction","volume":"74","author":"Tromp J","year":"2019","unstructured":"Tromp J, Shen L, Jhund PS, et al.. Age-related characteristics and outcomes of patients with heart\u00a0failure with preserved ejection fraction. J Am Coll Cardiol. 2019, 74:601-12. 10.1016\/j.jacc.2019.05.052","journal-title":"J Am Coll Cardiol"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031622","article-title":"Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction","volume":"137","author":"Pandey A","year":"2018","unstructured":"Pandey A, Omar W, Ayers C, et al.. Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Circulation. 2018, 137:1814-23. 10.1161\/CIRCULATIONAHA.117.031622","journal-title":"Circulation"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018574","article-title":"Sex differences in heart failure with preserved ejection fraction","volume":"10","author":"Sotomi Y","year":"2021","unstructured":"Sotomi Y, Hikoso S, Nakatani D, et al.. Sex differences in heart failure with preserved ejection fraction. J Am Heart Assoc. 2021, 10:e018574. 10.1161\/JAHA.120.018574","journal-title":"J Am Heart Assoc"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam CS","year":"2019","unstructured":"Lam CS, Arnott C, Beale AL, et al.. Sex differences in heart failure. Eur Heart J. 2019, 40:3859-3868c. 10.1093\/eurheartj\/ehz835","journal-title":"Eur Heart J"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding","volume":"9","author":"Simmonds SJ","year":"2020","unstructured":"Simmonds SJ, Cuijpers I, Heymans S, Jones EA. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells. 2020, 9:242. 10.3390\/cells9010242","journal-title":"Cells"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10204-8","article-title":"Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis","volume":"27","author":"Jin X","year":"2022","unstructured":"Jin X, Nauta JF, Hung CL, et al.. Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis. Heart Fail Rev. 2022, 27:1933-55. 10.1007\/s10741-021-10204-8","journal-title":"Heart Fail Rev"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23321","article-title":"Heart failure with preserved ejection fraction: new approaches to diagnosis and management","volume":"43","author":"Upadhya B","year":"2020","unstructured":"Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. Clin Cardiol. 2020, 43:145-55. 10.1002\/clc.23321","journal-title":"Clin Cardiol"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-09966-4","article-title":"Diagnostic algorithm for HFpEF: how much is the recent consensus applicable in clinical practice?","volume":"26","author":"Tadic M","year":"2021","unstructured":"Tadic M, Cuspidi C, Calicchio F, Grassi G, Mancia G. Diagnostic algorithm for HFpEF: how much is the recent consensus applicable in clinical practice?. Heart Fail Rev. 2021, 26:1485-93. 10.1007\/s10741-020-09966-4","journal-title":"Heart Fail Rev"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2020.04.154","article-title":"Epidemiology and pathogenesis of heart failure with preserved ejection fraction","volume":"21","author":"Nair N","year":"2020","unstructured":"Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020, 21:531-40. 10.31083\/j.rcm.2020.04.154","journal-title":"Rev Cardiovasc Med"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000481","article-title":"Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction","volume":"6","author":"Hummel SL","year":"2013","unstructured":"Hummel SL, Seymour EM, Brook RD, et al.. Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail. 2013, 6:1165-71. 10.1161\/CIRCHEARTFAILURE.113.000481","journal-title":"Circ Heart Fail"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1017\/S000711451500553X","article-title":"Dietary management of heart failure: room for improvement?","volume":"115","author":"Butler T","year":"2016","unstructured":"Butler T. Dietary management of heart failure: room for improvement?. Br J Nutr. 2016, 115:1202-17. 10.1017\/S000711451500553X","journal-title":"Br J Nutr"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01158-x","article-title":"Blood pressure in heart failure management and prevention","volume":"46","author":"Maeda D","year":"2023","unstructured":"Maeda D, Dotare T, Matsue Y, Teramoto K, Sunayama T, Tromp J, Minamino T. Blood pressure in heart failure management and prevention. Hypertens Res. 2023, 46:817-33. 10.1038\/s41440-022-01158-x","journal-title":"Hypertens Res"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield MM","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023, 329:827-38. 10.1001\/jama.2023.2020","journal-title":"JAMA"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to\u00a0heart\u00a0failure: contemporary update","volume":"5","author":"Messerli FH","year":"2017","unstructured":"Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to\u00a0heart\u00a0failure: contemporary update. JACC Heart Fail. 2017, 5:543-51. 10.1016\/j.jchf.2017.04.012","journal-title":"JACC Heart Fail"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012721.pub3","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction","volume":"5","author":"Martin N","year":"2021","unstructured":"Martin N, Manoharan K, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev. 2021, 5:CD012721. 10.1002\/14651858.CD012721.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto K","year":"2013","unstructured":"Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013, 15:110-8. 10.1093\/eurjhf\/hfs141","journal-title":"Eur J Heart Fail"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31963","article-title":"Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis","volume":"5","author":"Xiang B","year":"2022","unstructured":"Xiang B, Zhang R, Wu X, Zhou X. Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis. JAMA Netw Open. 2022, 5:e2231963. 10.1001\/jamanetworkopen.2022.31963","journal-title":"JAMA Netw Open"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.12.057","article-title":"Spironolactone in patients with heart\u00a0failure, preserved ejection fraction, and worsening renal function","volume":"77","author":"Beldhuis IE","year":"2021","unstructured":"Beldhuis IE, Myhre PL, Bristow M, et al.. Spironolactone in patients with heart\u00a0failure, preserved ejection fraction, and worsening renal function. J Am Coll Cardiol. 2021, 77:1211-21. 10.1016\/j.jacc.2020.12.057","journal-title":"J Am Coll Cardiol"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.762229","article-title":"Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"118","author":"Davis BR","year":"2008","unstructured":"Davis BR, Kostis JB, Simpson LM, et al.. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008, 118:2259-67. 10.1161\/CIRCULATIONAHA.107.762229","journal-title":"Circulation"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.2174\/1871529X22666220630164630","article-title":"Current updates in the pharmacotherapy of heart failure with a preserved ejection fraction","volume":"22","author":"Dahal R","year":"2022","unstructured":"Dahal R, Nickel N, Mukherjee D, Alkhateeb H. Current updates in the pharmacotherapy of heart failure with a preserved ejection fraction. Cardiovasc Hematol Disord Drug Targets. 2022, 22:87-95. 10.2174\/1871529X22666220630164630","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.2174\/1389450123666220906093058","article-title":"Digoxin and outcomes in patients with heart failure and preserved ejection fraction (HFpEF) patients: a systematic review and meta- analysis","volume":"24","author":"Hashemi-Shahri SH","year":"2023","unstructured":"Hashemi-Shahri SH, Aghajanloo A, Ghavami V, Arasteh O, Mohammadpour AH, Reiner \u017d, Sahebkar A. Digoxin and outcomes in patients with heart failure and preserved ejection fraction (HFpEF) patients: a systematic review and meta- analysis. Curr Drug Targets. 2023, 24:191-200. 10.2174\/1389450123666220906093058","journal-title":"Curr Drug Targets"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07371-7","article-title":"SGLT2-inhibitors on HFpEF patients. Role of ejection fraction","volume":"37","author":"Requena-Ibanez JA","year":"2022","unstructured":"Requena-Ibanez JA, Santos-Gallego CG, Zafar MU, Badimon JJ. SGLT2-inhibitors on HFpEF patients. Role of ejection fraction. Cardiovasc Drugs Ther. 2022, 37:989-96. 10.1007\/s10557-022-07371-7","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2022.03.010","article-title":"SGLT2 inhibitors and heart failure with preserved ejection fraction","volume":"18","author":"Jhund PS","year":"2022","unstructured":"Jhund PS. SGLT2 inhibitors and heart failure with preserved ejection fraction. Heart Fail Clin. 2022, 18:579-86. 10.1016\/j.hfc.2022.03.010","journal-title":"Heart Fail Clin"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2608","article-title":"Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: insights from the VICTORIA trial","volume":"24","author":"Senni M","year":"2022","unstructured":"Senni M, Alemayehu WG, Sim D, et al.. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: insights from the VICTORIA trial. Eur J Heart Fail. 2022, 24:1614-22. 10.1002\/ejhf.2608","journal-title":"Eur J Heart Fail"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-021-00501-6","article-title":"Reverse Cardiac Remodeling and ARNI Therapy","volume":"18","author":"Abboud A","year":"2021","unstructured":"Abboud A, Januzzi JL. Reverse Cardiac Remodeling and ARNI Therapy. Curr Heart Fail Rep. 2021, 18:71-83. 10.1007\/s11897-021-00501-6","journal-title":"Curr Heart Fail Rep"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.97.14.1382","article-title":"Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats","volume":"97","author":"Bozkurt B","year":"1998","unstructured":"Bozkurt B, Kribbs SB, Clubb FJ Jr, et al.. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998, 97:1382-91. 10.1161\/01.cir.97.14.1382","journal-title":"Circulation"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0b013e32835220b1","article-title":"Pulmonary hypertension in heart failure with preserved left ventricular ejection fraction: diagnosis and management","volume":"27","author":"Ohara T","year":"2012","unstructured":"Ohara T, Ohte N, Little WC. Pulmonary hypertension in heart failure with preserved left ventricular ejection fraction: diagnosis and management. Curr Opin Cardiol. 2012, 27:281-7. 10.1097\/HCO.0b013e32835220b1","journal-title":"Curr Opin Cardiol"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.003862","article-title":"INDIE-HFpEF (inorganic nitrite delivery to improve exercise capacity in heart failure with preserved ejection fraction): rationale and design","volume":"10","author":"Reddy YN","year":"2017","unstructured":"Reddy YN, Lewis GD, Shah SJ, et al.. INDIE-HFpEF (inorganic nitrite delivery to improve exercise capacity in heart failure with preserved ejection fraction): rationale and design. Circ Heart Fail. 2017, 10:e003862. 10.1161\/CIRCHEARTFAILURE.117.003862","journal-title":"Circ Heart Fail"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317342","article-title":"Right ventricle in heart failure with preserved ejection fraction","volume":"106","author":"Berglund F","year":"2020","unstructured":"Berglund F, Pi\u00f1a P, Herrera CJ. Right ventricle in heart failure with preserved ejection fraction. Heart. 2020, 106:1798-804. 10.1136\/heartjnl-2020-317342","journal-title":"Heart"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.014","article-title":"Exercise Intolerance in Older Adults With\u00a0Heart\u00a0Failure With Preserved Ejection\u00a0Fraction: JACC State-of-the-Art Review","volume":"78","author":"Pandey A","year":"2021","unstructured":"Pandey A, Shah SJ, Butler J, et al.. Exercise Intolerance in Older Adults With\u00a0Heart\u00a0Failure With Preserved Ejection\u00a0Fraction: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021, 78:1166-87. 10.1016\/j.jacc.2021.07.014","journal-title":"J Am Coll Cardiol"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.12.005","article-title":"The impact of patients with cardiac\u00a0amyloidosis in HFpEF trials","volume":"9","author":"Oghina S","year":"2021","unstructured":"Oghina S, Bougouin W, B\u00e9zard M, et al.. The impact of patients with cardiac\u00a0amyloidosis in HFpEF trials. JACC Heart Fail. 2021, 9:169-78. 10.1016\/j.jchf.2020.12.005","journal-title":"JACC Heart Fail"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-022-05122-w","article-title":"Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy","volume":"47","author":"H\u00e4nselmann A","year":"2022","unstructured":"H\u00e4nselmann A, Berliner D, Bauersachs J, Bavendiek U. Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy. Herz. 2022, 47:324-31. 10.1007\/s00059-022-05122-w","journal-title":"Herz"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/142252","article-title":"Updates for the diagnosis and management of cardiac amyloidosis","volume":"31","author":"Go\u015bciniak P","year":"2022","unstructured":"Go\u015bciniak P, Baron T, Milczarek S, Kostkiewicz M, Machali\u0144ski B. Updates for the diagnosis and management of cardiac amyloidosis. Adv Clin Exp Med. 2022, 31:175-85. 10.17219\/acem\/142252","journal-title":"Adv Clin Exp Med"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-023-01569-z","article-title":"[Transthyretin amyloid cardiomyopathy]","volume":"64","author":"Czepluch F","year":"2023","unstructured":"Czepluch F. [Transthyretin amyloid cardiomyopathy]. Inn Med (Heidelb). 2023, 64:823-9. 10.1007\/s00108-023-01569-z","journal-title":"Inn Med (Heidelb)"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-022-00578-7","article-title":"Biomarkers in HFpEF for diagnosis, prognosis, and biological phenotyping","volume":"19","author":"Eltelbany M","year":"2022","unstructured":"Eltelbany M, Shah P, deFilippi C. Biomarkers in HFpEF for diagnosis, prognosis, and biological phenotyping. Curr Heart Fail Rep. 2022, 19:412-24. 10.1007\/s11897-022-00578-7","journal-title":"Curr Heart Fail Rep"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen C","year":"2016","unstructured":"Franssen C, Chen S, Unger A, et al.. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016, 4:312-24. 10.1016\/j.jchf.2015.10.007","journal-title":"JACC Heart Fail"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function\u00a0in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn D","year":"2021","unstructured":"Kolijn D, Pabel S, Tian Y, et al.. Empagliflozin improves endothelial and cardiomyocyte function\u00a0in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovasc Res. 2021, 117:495-507. 10.1093\/cvr\/cvaa123","journal-title":"Cardiovasc Res"},{"key":"ref174","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel S","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, et al.. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018, 20:1690-700. 10.1002\/ejhf.1328","journal-title":"Eur J Heart Fail"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199700545-00009","article-title":"Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?","volume":"54 Suppl 5","author":"Remme WJ","year":"1997","unstructured":"Remme WJ. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?. Drugs. 1997, 54 Suppl 5:59-70. 10.2165\/00003495-199700545-00009","journal-title":"Drugs"},{"key":"ref176","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04359.x","article-title":"Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm","volume":"38","author":"O'Kane KP","year":"1994","unstructured":"O'Kane KP, Webb DJ, Collier JG, Vallance PJ. Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol. 1994, 38:311-5. 10.1111\/j.1365-2125.1994.tb04359.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref177","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1986.tb10177.x","article-title":"Effect of vasoactive peptides on prostacyclin synthesis in man","volume":"87","author":"Barrow SE","year":"1986","unstructured":"Barrow SE, Dollery CT, Heavey DJ, Hickling NE, Ritter JM, Vial J. Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol. 1986, 87:243-7. 10.1111\/j.1476-5381.1986.tb10177.x","journal-title":"Br J Pharmacol"},{"key":"ref178","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.71.1.137","article-title":"Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors","volume":"71","author":"Mombouli JV","year":"1992","unstructured":"Mombouli JV, Illiano S, Nagao T, Scott-Burden T, Vanhoutte PM. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res. 1992, 71:137-44. 10.1161\/01.res.71.1.137","journal-title":"Circ Res"},{"key":"ref179","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.89.4.1609","article-title":"Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure","volume":"89","author":"Schwarz M","year":"1994","unstructured":"Schwarz M, Katz SD, Demopoulos L, Hirsch H, Yuen JL, Jondeau G, LeJemtel TH. Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure. Circulation. 1994, 89:1609-14. 10.1161\/01.cir.89.4.1609","journal-title":"Circulation"},{"key":"ref180","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.625007","article-title":"Therapeutic strategies for endothelial dysfunction","volume":"11","author":"Deshpande DD","year":"2011","unstructured":"Deshpande DD, Janero DR, Amiji MM. Therapeutic strategies for endothelial dysfunction. Expert Opin Biol Ther. 2011, 11:1637-54. 10.1517\/14712598.2011.625007","journal-title":"Expert Opin Biol Ther"},{"key":"ref181","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.128009","article-title":"Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling","volume":"325","author":"Wohlfart P","year":"2008","unstructured":"Wohlfart P, Xu H, Endlich A, et al.. Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther. 2008, 325:370-9. 10.1124\/jpet.107.128009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref182","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01308.x","article-title":"AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats","volume":"163","author":"Yang Q","year":"2011","unstructured":"Yang Q, Xue HM, Wong WT, et al.. AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats. Br J Pharmacol. 2011, 163:1078-85. 10.1111\/j.1476-5381.2011.01308.x","journal-title":"Br J Pharmacol"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-015-0526-7","article-title":"The endothelium as a target for the treatment of heart failure","volume":"72","author":"Yang O","year":"2015","unstructured":"Yang O, Li J, Kong J. The endothelium as a target for the treatment of heart failure. Cell Biochem Biophys. 2015, 72:751-6. 10.1007\/s12013-015-0526-7","journal-title":"Cell Biochem Biophys"},{"key":"ref184","doi-asserted-by":"publisher","DOI":"10.1111\/apha.12646","article-title":"Endothelial dysfunction and vascular disease - a 30th anniversary update","volume":"219","author":"Vanhoutte PM","year":"2017","unstructured":"Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017, 219:22-96. 10.1111\/apha.12646","journal-title":"Acta Physiol (Oxf)"},{"key":"ref185","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.309813","article-title":"Endothelial functions","volume":"37","author":"Godo S","year":"2017","unstructured":"Godo S, Shimokawa H. Endothelial functions. Arterioscler Thromb Vasc Biol. 2017, 37:e108-14. 10.1161\/ATVBAHA.117.309813","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref186","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.84.4.1589","article-title":"Endothelium-dependent vasodilation is attenuated in patients with heart failure","volume":"84","author":"Kubo SH","year":"1991","unstructured":"Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991, 84:1589-96. 10.1161\/01.cir.84.4.1589","journal-title":"Circulation"},{"key":"ref187","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-804273-1.00024-7","article-title":"Chapter 24 - nitric oxide regulation of cardiovascular physiology and pathophysiology","author":"Dulce RA.","year":"2017","unstructured":"Dulce RA., Kulandavelu S, Schulman IH, Fritsch J, Hare KM. Chapter 24 - nitric oxide regulation of cardiovascular physiology and pathophysiology. Nitric oxide (third edition). Ignarro LJ, Freeman BA (ed): Academic Press, Massachusetts, United States; 2017. 313-38. 10.1016\/b978-0-12-804273-1.00024-7"},{"key":"ref188","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2014.04.008","article-title":"Phenotypic spectrum of heart failure with preserved ejection fraction","volume":"10","author":"Shah SJ","year":"2014","unstructured":"Shah SJ, Katz DH, Deo RC. Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Fail Clin. 2014, 10:407-18. 10.1016\/j.hfc.2014.04.008","journal-title":"Heart Fail Clin"},{"key":"ref189","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.09.006","article-title":"Biological phenotypes of heart failure with preserved ejection fraction","volume":"70","author":"Lewis GA","year":"2017","unstructured":"Lewis GA, Schelbert EB, Williams SG, Cunnington C, Ahmed F, McDonagh TA, Miller CA. Biological phenotypes of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2017, 70:2186-200. 10.1016\/j.jacc.2017.09.006","journal-title":"J Am Coll Cardiol"},{"key":"ref190","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah SJ","year":"2015","unstructured":"Shah SJ, Katz DH, Selvaraj S, et al.. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015, 131:269-79. 10.1161\/CIRCULATIONAHA.114.010637","journal-title":"Circulation"},{"key":"ref191","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2012.123","article-title":"The many faces of heart failure with preserved ejection fraction","volume":"9","author":"Shah AM","year":"2012","unstructured":"Shah AM, Pfeffer MA. The many faces of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2012, 9:555-6. 10.1038\/nrcardio.2012.123","journal-title":"Nat Rev Cardiol"},{"key":"ref192","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs124","article-title":"Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction","volume":"33","author":"Shah AM","year":"2012","unstructured":"Shah AM, Solomon SD. Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction. Eur Heart J. 2012, 33:1716-7. 10.1093\/eurheartj\/ehs124","journal-title":"Eur Heart J"},{"key":"ref193","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.010","article-title":"Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter","volume":"62","author":"Shah SJ","year":"2013","unstructured":"Shah SJ. Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter. J Am Coll Cardiol. 2013, 62:1339-42. 10.1016\/j.jacc.2013.07.010","journal-title":"J Am Coll Cardiol"},{"key":"ref194","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfp142","article-title":"Adherence to medication according to sex and age in the CHARM programme","volume":"11","author":"Granger BB","year":"2009","unstructured":"Granger BB, Ekman I, Granger CB, et al.. Adherence to medication according to sex and age in the CHARM programme. Eur J Heart Fail. 2009, 11:1092-8. 10.1093\/eurjhf\/hfp142","journal-title":"Eur J Heart Fail"},{"key":"ref195","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq091","article-title":"Compliance with non-pharmacological recommendations and outcome in heart failure patients","volume":"31","author":"van der Wal MH","year":"2010","unstructured":"van der Wal MH, van Veldhuisen DJ, Veeger NJ, Rutten FH, Jaarsma T. Compliance with non-pharmacological recommendations and outcome in heart failure patients. Eur Heart J. 2010, 31:1486-93. 10.1093\/eurheartj\/ehq091","journal-title":"Eur Heart J"},{"key":"ref196","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.87.4.643","article-title":"Factors contributing to the hospitalization of patients with congestive heart failure","volume":"87","author":"Chin MH","year":"1997","unstructured":"Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health. 1997, 87:643-8. 10.2105\/ajph.87.4.643","journal-title":"Am J Public Health"},{"key":"ref197","doi-asserted-by":"publisher","DOI":"10.1093\/her\/cyn004","article-title":"Understanding tailoring in communicating about health","volume":"23","author":"Hawkins RP","year":"2008","unstructured":"Hawkins RP, Kreuter M, Resnicow K, Fishbein M, Dijkstra A. Understanding tailoring in communicating about health. Health Educ Res. 2008, 23:454-66. 10.1093\/her\/cyn004","journal-title":"Health Educ Res"},{"key":"ref198","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002826","article-title":"Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes","volume":"9","author":"Nadruz W Jr","year":"2016","unstructured":"Nadruz W Jr, West E, Santos M, Skali H, Groarke JD, Forman DE, Shah AM. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail. 2016, 9:e002826. 10.1161\/CIRCHEARTFAILURE.115.002826","journal-title":"Circ Heart Fail"},{"key":"ref199","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056600","article-title":"Distinct transcriptomic and proteomic profile specifies patients who have heart failure with potential of myocardial recovery on mechanical unloading and circulatory support","volume":"147","author":"Drakos SG","year":"2023","unstructured":"Drakos SG, Badolia R, Makaju A, et al.. Distinct transcriptomic and proteomic profile specifies patients who have heart failure with potential of myocardial recovery on mechanical unloading and circulatory support. Circulation. 2023, 147:409-24. 10.1161\/CIRCULATIONAHA.121.056600","journal-title":"Circulation"},{"key":"ref200","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac098","article-title":"Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction","volume":"118","author":"Dulce RA","year":"2023","unstructured":"Dulce RA, Kanashiro-Takeuchi RM, Takeuchi LM, et al.. Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction. Cardiovasc Res. 2023, 118:3586-601. 10.1093\/cvr\/cvac098","journal-title":"Cardiovasc Res"},{"key":"ref201","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65255-y","article-title":"Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension","volume":"10","author":"Mishra M","year":"2020","unstructured":"Mishra M, Muthuramu I, Kempen H, De Geest B. Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension. Sci Rep. 2020, 10:8382. 10.1038\/s41598-020-65255-y","journal-title":"Sci Rep"},{"key":"ref202","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009288","article-title":"Transcutaneous vagus nerve stimulation ameliorates the phenotype of heart failure with preserved ejection fraction through its anti-inflammatory effects","volume":"15","author":"Elkholey K","year":"2022","unstructured":"Elkholey K, Niewiadomska M, Morris L, Whyte S, Houser J, Humphrey MB, Stavrakis S. Transcutaneous vagus nerve stimulation ameliorates the phenotype of heart failure with preserved ejection fraction through its anti-inflammatory effects. Circ Heart Fail. 2022, 15:e009288. 10.1161\/CIRCHEARTFAILURE.122.009288","journal-title":"Circ Heart Fail"},{"key":"ref203","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2019.06.004","article-title":"Use of speckle tracking to assess heart failure with preserved ejection fraction","volume":"74","author":"Hiebert JB","year":"2019","unstructured":"Hiebert JB, Vacek J, Shah Z, Rahman F, Pierce JD. Use of speckle tracking to assess heart failure with preserved ejection fraction. J Cardiol. 2019, 74:397-402. 10.1016\/j.jjcc.2019.06.004","journal-title":"J Cardiol"},{"key":"ref204","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.06.013","article-title":"Machine learning prediction of mortality and hospitalization in heart failure with preserved ejection fraction","volume":"8","author":"Angraal S","year":"2020","unstructured":"Angraal S, Mortazavi BJ, Gupta A, et al.. Machine learning prediction of mortality and hospitalization in heart failure with preserved ejection fraction. JACC Heart Fail. 2020, 8:12-21. 10.1016\/j.jchf.2019.06.013","journal-title":"JACC Heart Fail"},{"key":"ref205","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-13-1-4","article-title":"The role of estrogen in cardiac metabolism and diastolic function","volume":"13","author":"Li S","year":"2017","unstructured":"Li S, Gupte AA. The role of estrogen in cardiac metabolism and diastolic function. Methodist Debakey Cardiovasc J. 2017, 13:4-8. 10.14797\/mdcj-13-1-4","journal-title":"Methodist Debakey Cardiovasc J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184757-heart-failure-with-preserved-ejection-fraction-an-evolving-understanding","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:00Z","timestamp":1707509340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184757-heart-failure-with-preserved-ejection-fraction-an-evolving-understanding"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":205,"URL":"https:\/\/doi.org\/10.7759\/cureus.46152","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}